Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OPTIMISING MOLECULAR RADIONUCLIDE THERAPY: The Role of Quantitative SPECT/CT & PET/CT and Radiation Dosimetry (SELFIE)

NCT04922801 is registered in ClinicalTrials.gov with King's College London as lead sponsor.

NCT NCT04922801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04922801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OPTIMISING MOLECULAR RADIONUCLIDE THERAPY: The Role of Quantitative SPECT/CT & PET/CT and Radiation Dosimetry (SELFIE)
Lead sponsor
King's College London
Phase
Observational
Overall status
Completed
Start date
December 9, 2021
Completion date
November 5, 2022
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hyperthyroidism, neuroendocrine tumors, thyroid cancer, thyroid carcinoma